Aerpio Pharmaceuticals (ARPO) Given a $9.00 Price Target by HC Wainwright Analysts

Share on StockTwits

Aerpio Pharmaceuticals (OTCMKTS:ARPO) received a $9.00 price objective from analysts at HC Wainwright in a research note issued to investors on Monday. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 368.75% from the stock’s current price.

Several other analysts have also recently issued reports on the company. Zacks Investment Research upgraded Aerpio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 price objective on the stock in a research note on Monday, August 20th. Needham & Company LLC assumed coverage on Aerpio Pharmaceuticals in a research note on Monday, July 23rd. They set a “buy” rating and a $10.00 price objective on the stock. Finally, Guggenheim assumed coverage on Aerpio Pharmaceuticals in a research note on Wednesday, September 19th. They set a “buy” rating and a $10.00 price objective on the stock.

OTCMKTS:ARPO opened at $1.92 on Monday. Aerpio Pharmaceuticals has a one year low of $1.85 and a one year high of $6.10.

Aerpio Pharmaceuticals (OTCMKTS:ARPO) last released its quarterly earnings results on Tuesday, August 14th. The company reported ($0.22) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.02. The business had revenue of $1.33 million during the quarter. As a group, equities analysts anticipate that Aerpio Pharmaceuticals will post -0.89 EPS for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Millennium Management LLC bought a new position in shares of Aerpio Pharmaceuticals during the second quarter valued at approximately $934,000. Nexthera Capital LP bought a new position in shares of Aerpio Pharmaceuticals during the second quarter valued at approximately $1,240,000. FMR LLC bought a new position in shares of Aerpio Pharmaceuticals during the second quarter valued at approximately $3,648,000. Finally, Orbimed Advisors LLC bought a new position in shares of Aerpio Pharmaceuticals during the second quarter valued at approximately $21,555,000. Hedge funds and other institutional investors own 0.37% of the company’s stock.

About Aerpio Pharmaceuticals

Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema.

Featured Article: Why do companies engage in swaps?

Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply